Ensign Peak Advisors
EW icon

Ensign Peak Advisors’s Edwards Lifesciences EW Stock Holding History

Ensign Peak Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Sell
159,272
-95,964
-38% -$8.04M 0.02% 377
2026
Q1 		$20.4M Buy
255,236
+4,922
+2% +$406K 0.04% 302
2025
Q4 		$21.3M Buy
250,314
+18,945
+8% +$1.55M 0.04% 282
2025
Q3 		$18M Buy
231,369
+48,061
+26% +$3.76M 0.03% 329
2025
Q2 		$14.3M Sell
183,308
-8,533
-4% -$636K 0.02% 388
2025
Q1 		$13.9M Sell
191,841
-19,895
-9% -$1.42M 0.03% 382
2024
Q4 		$15.7M Sell
211,736
-10,950
-5% -$766K 0.03% 362
2024
Q3 		$14.7M Sell
222,686
-17,200
-7% -$1.25M 0.03% 381
2024
Q2 		$22.2M Sell
239,886
-25,590
-10% -$2.27M 0.04% 301
2024
Q1 		$25.4M Buy
265,476
+3,949
+2% +$332K 0.05% 279
2023
Q4 		$19.9M Buy
261,527
+29,234
+13% +$2.03M 0.04% 299
2023
Q3 		$16.1M Sell
232,293
-9,171
-4% -$737K 0.03% 299
2023
Q2 		$22.8M Buy
241,464
+10,610
+5% +$922K 0.05% 275
2023
Q1 		$19.1M Sell
230,854
-93,366
-29% -$7.34M 0.04% 288
2022
Q4 		$24.2M Buy
324,220
+258,313
+392% +$19.9M 0.05% 266
2022
Q3 		$5.45M Sell
65,907
-3,485
-5% -$335K 0.01% 504
2022
Q2 		$6.6M Sell
69,392
-3,430
-5% -$355K 0.02% 464
2022
Q1 		$8.57M Sell
72,822
-110,205
-60% -$12.4M 0.02% 460
2021
Q4 		$23.7M Buy
183,027
+116,418
+175% +$13.6M 0.05% 291
2021
Q3 		$7.54M Buy
66,609
+114
+0.2% +$13K 0.02% 508
2021
Q2 		$6.89M Sell
66,495
-8,570
-11% -$808K 0.01% 534
2021
Q1 		$6.28M Sell
75,065
-23,315
-24% -$1.97M 0.01% 547
2020
Q4 		$8.97M Sell
98,380
-224,565
-70% -$18.6M 0.02% 440
2020
Q3 		$25.8M Buy
322,945
+82,730
+34% +$6.46M 0.07% 256
2020
Q2 		$16.6M Buy
240,215
+93,386
+64% +$6.64M 0.05% 325
2020
Q1 		$9.23M Sell
146,829
-82,230
-36% -$5.93M 0.03% 368
2019
Q4 		$17.8M Buy
+229,059
New +$17.9M 0.05% 307

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Ensign Peak Advisors's EW Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Edwards Lifesciences (EW) stake by 38% in Q2 2026, selling an estimated $8.04M and leaving 159,272 shares worth $14.4M. The position accounts for 0.02% of the portfolio, ranked #377.

Ensign Peak Advisors first reported a position in EW in Q4 2019 and has held it in 27 quarters since. The position peaked at $25.8M in Q3 2020. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Ensign Peak Advisors held 159,272 shares of Edwards Lifesciences worth $14.4M as of Q2 2026.
  • Ensign Peak Advisors sold 95,964 Edwards Lifesciences shares in Q2 2026, an estimated $8.04M.
  • Edwards Lifesciences made up 0.02% of Ensign Peak Advisors's portfolio in Q2 2026, its #377 holding.
  • Ensign Peak Advisors first reported a position in Edwards Lifesciences in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Edwards Lifesciences position peaked at $25.8M in Q3 2020.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.